Learning Objectives:

1.       Review current initial therapy for patients with CLL who are <65 years old
2.        Review the role of ibrutinib in CLL treatment currently
3.        Discuss the future of ibrutinib as a possible first line therapy for patients <65 years old

Learning Objectives:

1. Understand the prognostic implication of cell of origin in DLBCL and identify emerging therapies for specific subtypes by cell of origin classification
2. Define double-expressing lymphoma and its interaction with cell of origin
3. Understand whom to test for “double-hit” lymphoma and current treatment recommendations